ADM TRONICS UNLIMITED, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ADM TRONICS UNLIMITED, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Mar 31, 2018 | $3.75M | Jul 16, 2018 |
| FY2018 | Dec 31, 2017 | $1.02M | Jul 16, 2018 |
| FY2018 | Sep 30, 2017 | $931.1K | Jul 16, 2018 |
| FY2018 | Jun 30, 2017 | $1.15M | Jul 16, 2018 |
| FY2018 | Mar 31, 2017 | $5.27M | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | $4.51M | Jun 29, 2017 |
| FY2016 | Mar 31, 2015 | $2.85M | Jul 13, 2016 |
| FY2015 | Mar 31, 2014 | $1.81M | Jul 14, 2015 |
| FY2014 | Mar 31, 2013 | $1.58M | Jul 15, 2014 |
| FY2012 | Mar 31, 2012 | $2.32M | Jul 15, 2013 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.40M | Jul 14, 2025 |
| FY2025 | Mar 31, 2024 | $1.12M | Jul 14, 2025 |
| FY2024 | Mar 31, 2023 | $1.66M | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | $1.25M | Jul 17, 2023 |
| FY2022 | Mar 31, 2021 | $1.16M | Jul 8, 2022 |
| FY2021 | Mar 31, 2020 | $1.57M | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | $1.56M | Jul 14, 2020 |
| FY2019 | Mar 31, 2018 | $1.89M | Jul 31, 2019 |
| FY2018 | Dec 31, 2017 | $550.0K | Jul 16, 2018 |
| FY2018 | Sep 30, 2017 | $579.2K | Jul 16, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($123.1K) | Jul 14, 2025 |
| FY2025 | Mar 31, 2024 | ($877.2K) | Jul 14, 2025 |
| FY2024 | Mar 31, 2023 | ($96.3K) | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | ($1.38M) | Jul 17, 2023 |
| FY2022 | Mar 31, 2021 | ($598.3K) | Jul 8, 2022 |
| FY2021 | Mar 31, 2020 | ($95.8K) | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | ($342.6K) | Jul 14, 2020 |
| FY2019 | Mar 31, 2018 | $109.7K | Jul 31, 2019 |
| FY2018 | Dec 31, 2017 | ($147.7K) | Jul 16, 2018 |
| FY2018 | Sep 30, 2017 | $36 | Jul 16, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($94.0K) | Jul 14, 2025 |
| FY2025 | Mar 31, 2024 | ($819.9K) | Jul 14, 2025 |
| FY2024 | Mar 31, 2023 | $30.3K | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | ($1.13M) | Jul 17, 2023 |
| FY2022 | Mar 31, 2021 | ($680.5K) | Jul 8, 2022 |
| FY2021 | Mar 31, 2020 | ($43.4K) | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | ($374.7K) | Jul 14, 2020 |
| FY2019 | Mar 31, 2018 | ($66.2K) | Jul 31, 2019 |
| FY2018 | Dec 31, 2017 | $83.8K | Jul 16, 2018 |
| FY2018 | Sep 30, 2017 | $76.8K | Jul 16, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $517.3K | Jul 14, 2025 |
| FY2025 | Mar 31, 2024 | $576.9K | Jul 14, 2025 |
| FY2024 | Mar 31, 2023 | $541.2K | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | $615.9K | Jul 17, 2023 |
| FY2022 | Mar 31, 2021 | $656.0K | Jul 8, 2022 |
| FY2021 | Mar 31, 2020 | $589.4K | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | $673.9K | Jul 14, 2020 |
| FY2019 | Mar 31, 2018 | $527.7K | Jul 31, 2019 |
| FY2018 | Mar 31, 2017 | $168.8K | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | $91.8K | Jun 29, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $972.4K | Jul 14, 2025 |
| FY2025 | Mar 31, 2024 | $1.36M | Jul 14, 2025 |
| FY2024 | Mar 31, 2023 | $1.09M | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | $1.76M | Jul 17, 2023 |
| FY2022 | Mar 31, 2021 | $1.05M | Jul 8, 2022 |
| FY2021 | Mar 31, 2020 | $923.3K | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | $1.24M | Jul 14, 2020 |
| FY2019 | Mar 31, 2018 | $1.40M | Jul 31, 2019 |
| FY2018 | Mar 31, 2017 | $1.24M | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | $1.45M | Jun 29, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $10.0K | Jul 14, 2025 |
| FY2025 | Mar 31, 2024 | ($709.9K) | Jul 14, 2025 |
| FY2024 | Mar 31, 2023 | $125.0K | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | ($476.2K) | Jul 17, 2023 |
| FY2022 | Mar 31, 2021 | ($769.6K) | Jul 8, 2022 |
| FY2021 | Mar 31, 2020 | $109.3K | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | ($275.5K) | Jul 14, 2020 |
| FY2019 | Mar 31, 2018 | ($259.9K) | Jul 31, 2019 |
| FY2018 | Mar 31, 2017 | $492.9K | Jul 16, 2018 |
| FY2016 | Mar 31, 2016 | $935.2K | Jul 13, 2016 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Mar 31, 2012 | $2.3K | Jun 29, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $2.13M | Jul 14, 2025 |
| FY2025 | Mar 31, 2024 | $2.14M | Jul 14, 2025 |
| FY2024 | Mar 31, 2023 | $3.09M | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | $3.35M | Jul 17, 2023 |
| FY2022 | Mar 31, 2021 | $5.21M | Jul 8, 2022 |
| FY2021 | Mar 31, 2020 | $5.05M | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | $4.55M | Jul 14, 2020 |
| FY2019 | Mar 31, 2018 | $4.55M | Jul 31, 2019 |
| FY2018 | Mar 31, 2017 | $4.52M | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | $3.42M | Jun 29, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.46M | Jul 14, 2025 |
| FY2025 | Mar 31, 2024 | $1.45M | Jul 14, 2025 |
| FY2024 | Mar 31, 2023 | $1.52M | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | $1.98M | Jul 17, 2023 |
| FY2022 | Mar 31, 2021 | $2.46M | Jul 8, 2022 |
| FY2021 | Mar 31, 2020 | $1.71M | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | $1.11M | Jul 14, 2020 |
| FY2019 | Mar 31, 2018 | $774.9K | Jul 31, 2019 |
| FY2018 | Mar 31, 2017 | $853.1K | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | $1.06M | Jun 29, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $671.3K | Jul 14, 2025 |
| FY2025 | Mar 31, 2024 | $692.4K | Jul 14, 2025 |
| FY2025 | Mar 31, 2023 | $1.57M | Jul 14, 2025 |
| FY2024 | Mar 31, 2022 | $1.37M | Jul 15, 2024 |
| FY2023 | Mar 31, 2021 | $2.76M | Jul 17, 2023 |
| FY2022 | Mar 31, 2020 | $3.34M | Jul 8, 2022 |
| FY2021 | Mar 31, 2019 | $3.43M | Jul 14, 2021 |
| FY2020 | Mar 31, 2018 | $3.78M | Jul 14, 2020 |
| FY2019 | Mar 31, 2017 | $3.67M | Jul 31, 2019 |
| FY2018 | Mar 31, 2016 | $2.36M | Jul 16, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($32.97M) | Jul 14, 2025 |
| FY2025 | Mar 31, 2024 | ($32.95M) | Jul 14, 2025 |
| FY2024 | Mar 31, 2023 | ($32.07M) | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | ($31.97M) | Jul 17, 2023 |
| FY2022 | Mar 31, 2021 | ($30.59M) | Jul 8, 2022 |
| FY2021 | Mar 31, 2020 | ($29.99M) | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | ($29.89M) | Jul 14, 2020 |
| FY2019 | Mar 31, 2018 | ($29.55M) | Jul 31, 2019 |
| FY2018 | Mar 31, 2017 | ($29.66M) | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | ($30.87M) | Jun 29, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $383.0K | Jul 14, 2025 |
| FY2025 | Mar 31, 2024 | $537.0K | Jul 14, 2025 |
| FY2024 | Mar 31, 2023 | $1.00M | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | $1.14M | Jul 17, 2023 |
| FY2022 | Mar 31, 2021 | $1.55M | Jul 8, 2022 |
| FY2021 | Mar 31, 2020 | $1.44M | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | $1.56M | Jul 14, 2020 |
| FY2020 | Mar 31, 2018 | $1.69M | Jul 14, 2020 |
| FY2019 | Mar 31, 2017 | $1.98M | Jul 31, 2019 |
| FY2018 | Mar 31, 2016 | $1.40M | Jul 16, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jul 14, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jul 14, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Jul 17, 2023 |
| FY2022 | Mar 31, 2021 | 0 | Jul 8, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 67.59M | Jul 14, 2025 |
| FY2025 | Mar 31, 2024 | 67.59M | Jul 14, 2025 |
| FY2024 | Mar 31, 2023 | 67.59M | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | 67.59M | Jul 17, 2023 |
| FY2022 | Mar 31, 2021 | 67.59M | Jul 8, 2022 |
| FY2021 | Mar 31, 2020 | 67.59M | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | 67.59M | Jul 14, 2020 |
| FY2019 | Mar 31, 2018 | 67.59M | Jul 31, 2019 |
| FY2018 | Mar 31, 2017 | 67.59M | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | 67.01M | Jun 29, 2017 |